Alzinova

0,58 SEK

-1,35 %

Mindre end 1K følgere

ALZ

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Oversigt

Finansielt overblik og estimater

Ejerskab

Dividend

Investorkonsensus

-1,35 %

-24,77 %

-29,67 %

-69,60 %

-59,06 %

-79,33 %

-81,16 %

-89,97 %

-91,87 %

Alzinova is a biotechnology company. The company specializes in the therapeutic treatment of Alzheimer's and conducts research and development of peptides that are further developed as vaccines. In addition, the company also develops various research tools within the field of work. The largest operations are found in the Nordic market. The company was founded in 2011 and has its headquarters in Mölndal.

Markedsværdi

90,01 mio. SEK

Aktieomsætning

84,7 t SEK

Omsætning

-

EBIT %

-

P/E

-

Udbytteafkast, %

-

Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender

25.3

2026

Årsrapport '25

14.5

2026

Delårsrapport Q1'26

26.5

2026

Generalforsamling '26

Alle

Selskabsmeddelelser

Eksterne analyser

ViserAlle indholdstyper

Pressemeddelelsei går

Alzinova to participate in several international industry and investor events during spring and summer 2026

Selskabsmeddelelse25.2.2026, 14.12

Alzinova announces final outcome of the rights issue

Pressemeddelelse25.2.2026, 12.00

DNB Carnegie Access: Alzinova - Beyond plaques: the scientific rationale behind ALZ-101

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto

Følgere og notifikationer om fulgte virksomheder

Analytikerkommentarer og anbefalinger

Værktøj til at sammenligne aktier og andre populære værktøjer

Selskabsmeddelelse23.2.2026, 21.57

Alzinova announces preliminary outcome of the rights issue

Selskabsmeddelelse17.2.2026, 07.30

Last day of trading in unit rights in Alzinovas rights issue

Selskabsmeddelelse16.2.2026, 12.00

Alzinova engages renowned international Alzheimer’s expert as Global Principal Investigator ahead of planned Phase 2 study

Selskabsmeddelelse6.2.2026, 07.45

The subscription period in Alzinovas rights issue of units starts today

Selskabsmeddelelse3.2.2026, 13.50

Alzinova publishes prospectus in connection with rights issue of units

Pressemeddelelse19.1.2026, 13.30

Alzinova advanced partner discussions at the J.P. Morgan Healthcare Conference in San Francisco

Pressemeddelelse30.12.2025, 07.53

BioStock: Alzinova comments on SEK 50 million rights issue

Pressemeddelelse22.12.2025, 10.11

DNB Carnegie Access: Alzinova: Aims to raise cSEK50m

Selskabsmeddelelse19.12.2025, 17.14

The Board of Directors of Alzinova resolves on a rights issue of units of approximately SEK 50 million

Pressemeddelelse9.12.2025, 11.25

BioStock: Alzinova comments on the Letter of Intent in Saudi Arabia

Pressemeddelelse5.12.2025, 10.09

BioStock: Alzinova signs Letter of Intent with Saudi Arabian stakeholder

Pressemeddelelse4.12.2025, 12.46

DNB Carnegie Access: Alzinova: Memorandum of Understanding for commercial partnership in Saudi Arabia

Selskabsmeddelelse4.12.2025, 10.00

Alzinova enters memorandum of understanding for commercial partnership

Pressemeddelelse13.11.2025, 17.24

Redeye: Alzinova (Q3 review) - Regulatory progress in anticipation of a deal

Pressemeddelelse13.11.2025, 17.18

DNB Carnegie Access: Alzinova: Progress hinges on partnership execution – Q3 review

Pressemeddelelse13.11.2025, 13.07

BioStock: FDA approval and strong data position Alzinova ahead of Phase II

Selskabsmeddelelse13.11.2025, 06.45

Alzinova publishes interim report for January – September 2025

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.